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The immune landscape in brain metastasis is a very heterogeneous framework.
Amongst a broad plethora of cells within the tumor microenvironment, the presence
of activated microglia has been perfectly described. The innate role of microglial cells
is to detect and eliminate any insults that may disturb the regular behavior of the brain.
As part of its defensive role, it releases pro- and anti-inflammatory cytokines that aim
to modulate the inflammatory scenario at the metastatic foci. However, the long term
effects that these cells may exert on the metastatic progression is not clear. One of
the biggest challenges in the field is to distinguish between brain resident microglial
cells and infiltrated bone-marrow derived macrophages. Part of this issue is the fact that
both cell types share similar phenotypes. Current studies are based on the modulation of
the immune response against cancer cells (immunotherapy). However, most of current
clinical trials and newly developed drugs focus on the adaptive immune response
(e.g., immune blockade check-points). Additionally, the unique structure of the central
nervous system with the presence of the blood-brain barrier have hindered a significant
advance in novel therapies against brain metastasis. In this manuscript, we describe
current advances in characterization of tumor-associated microglia and macrophages,
the importance of microglia during the anti-cancerous response, and the future direction
for the development of new strategies against this complex disease.
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INTRODUCTION
At the beginning of the last century, Río-Hortega (1919) was the first scientist to describe a new type
of resident cells within the central nervous system (CNS), which he termed microglia. This was the
first study that clearly differentiated these cells from the “third brain element” (glial cells) described
by Ramón y Cajal (1913) years earlier. Even back then, owing to his interests in neuropathology,
Hortega pioneered research into the important role of microglia in CNS tumors (Pérez-Cerdá et al.,
2015).
Currently, the use of pre-clinical models has helped us to delve into the importance of this
unique brain cell type. Microglia are mostly present in the gray matter, particularly in the
hippocampus, olfactory telencephalon, basal ganglia, and substantia nigra. The distribution of these
cells in adult mouse brains fluctuates from 5% in the cortex to 12% in the substantia nigra (Lawson
et al., 1990; Yang et al., 2013). Nevertheless, the key role of microglia in the field of oncology is
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still an area of substantial investigation. Numerous primary
cancers are able to colonize the brain. Specifically, lung,
melanoma and breast cancer present the highest incidence of
brain metastasis (Fidler, 2015). These patients have significantly
increased life expectancy owing to better treatments for the
primary tumor. However, this improvement comes with a
higher risk of suffering from the colonization of distant organs.
Therefore, rather than the primary origin, the metastatic spread
of circulating tumor cells to distant sites (metastasis) is the major
cause of cancer demise (Chaffer and Weinberg, 2011; Lambert
et al., 2017). Consequently, the incidence of brain metastases
(metastatic spread to the central nervous system, BM has become
a significant clinical problem (Lowery and Yu, 2017). The poor
patient life expectancy, measured just in months, because of the
late diagnosis and the lack of efficient treatments, make this
disease one of the biggest challenges in the 21st century.
However, it is worth mentioning that metastatic colonization
is a very inefficient process in which most cells die and only a
minimal population survive and successfully establish metastases
(Weiss, 1990). The reasons for the poor efficacy of this multi-
step process are shear stress within the blood vessels, immune
surveillance and oxidative stress (Massagué and Obenauf, 2016),
commonly led by microglial cells.
In this manuscript, we aim at describing the complex biology
of microglial cells within the CNS during metastasis progression
and the importance of microglia and macrophages as future
components of anti-metastatic therapies.
WHEN THE PRIVILEGED IMMUNE
NATURE OF THE BRAIN IS
COMPROMISED
Despite recent findings concerning the role of the glymphatic
system in the CNS (Louveau et al., 2017), the brain is
still considered to possess a privileged immune environment
owing to the presence of the blood-brain barrier (BBB) and
its resident defensive system. The BBB impedes undesired
factors in the blood and lymph from crossing into the brain
parenchyma. Amongst the different components of the BBB,
endothelial cells, pericytes, and astrocytes are the main players
in CNS integrity (Persidsky et al., 2006). However, certain
populations of circulating tumor cells have the ability to cross
this ontogenetically evolved hurdle and thrive in the brain
parenchyma.
It has long been described that tumor cells share the same
abilities as leukocytes to cross into the brain parenchyma
(Strell and Entschladen, 2008). During metastatic colonization,
the structure of the BBB is transiently compromised by the
paracellular and transcellular extravasation of tumor cells and
the release of tissue-disrupting soluble factors (e.g., cytokines)
(Wilhelm et al., 2013). After this transient disruption of the
tight junction network, microglia can contribute to regulating
BBB integrity (da Fonseca et al., 2014), and also repair the
BBB following cerebrovascular damage in a purinergic receptor
P2RY12-dependent manner (Lou et al., 2016). Microglia express
high levels of P2RY12, which serve as chemotactic receptor
at sites of CNS injury. Microglia can aggregate and form a
physical barrier (via E-cadherin upregulation) that will engulf the
damaged vessel wall and temporarily assume BBB functions.
Subsequently, during the development and growth phase of
brain metastases, microglia show an impaired immune response
evolving, it is thought, into a tumor-supportive phenotype
(Pukrop et al., 2010; Roesch et al., 2018). Microglia and
infiltrating macrophages are important components of the tumor
microenvironment (TME). In regular homeostatic conditions,
microglia remain resting or quiescent, but in response to disease
or injury, including tumor cell invasion, they become activated.
These cells can adopt many different states of polarization
during cancer progression that fluctuates across a pro- to anti-
inflammatory spectrum (Wang et al., 2014). Those immune
cells with a pro-inflammatory phenotype have been described
as exerting an anti-tumorigenic effect whilst those with an
anti-inflammatory profile have shown tumor-supporting activity
(Pukrop et al., 2010; Wang et al., 2014). The mechanisms
underlying the phenotypic switch between these two states and
the potential coexistence of both identities are far from being
understood in a brain metastasis context. However, what it is
clearly known is that, during systemic metastasis, cancer cells
have the ability to drive surrounding immune cells into a tumor
supportive phenotype (Sica et al., 2006; Hao et al., 2012).
MICROGLIA VERSUS BONE
MARROW-DERIVED MACROPHAGES
(BMDM)
The activation of microglia surrounding metastatic loci has
been clearly described. Our group has characterized such
activation identifying a broad panel of proteins (cellular adhesion
molecules, CAMs; e.g., LFA-1, ALCAM, and E-selectin) that
are highly upregulated in tumor-associated microglia together
with other brain cell types (e.g., endothelial cells and astrocytes)
within the TME (Soto et al., 2014). However, it is clear
that the macrophage population within the brain TME is not
restricted to tissue-resident macrophages (microglia), but also
includes recruited bone marrow-derived macrophages (BMDMs)
(Bowman et al., 2016). Microglia develop from embryonic yolk
sac progenitor cells (Ginhoux et al., 2010) and persist in the CNS
into adulthood (Ajami et al., 2007). By contrast, in response to
homeostasis disturbance, circulating monocytes are recruited to
the brain parenchyma and give rise to BMDMs (Shi and Pamer,
2011). Whether microglia and BMDMs have distinct functions in
the brain tumor microenvironment has been controversial, and is
a topic of active investigation. Importantly, microglial activation
and presence is not just relevant in brain metastasis (Sevenich
et al., 2014). For instance, in glioblastoma, the most aggressive
form of solid cancer in the CNS, microglia and BMDMs comprise
up to 30–50% of the total tumor mass (Badie and Schartner, 2000;
Pyonteck et al., 2013), suggesting a critical role for these cell types
during tumor progression within the CNS more generally.
Differentiating between microglia and BMDMs is not
straightforward. Microglia and infiltrated macrophages
share similar morphology, partly imposed by the local
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microenvironment within the CNS. Differential CD45 expression
has been suggested to distinguish between microglia (CD45low)
and BMDMs (CD45high) in murine models, however, this
does not seem to correlate with human brain tumor studies
(Bowman et al., 2016). Recently, genetically engineered mouse
models have provided means to distinguish between BMDM
and resident microglia (Mizutani et al., 2012). Mizutani and
collaborators generated a chimeric mouse where microglial
cells were exclusively CX3CR1-GFP+, whilst hematogenous
leukocytes were CCR2-RFP+. This model has helped to identify
the role of each cell subpopulation during embryogenesis and
disease (Bennett et al., 2016). However, these approaches are
clearly not of relevance to human investigation (Sevenich, 2018).
Very recently, the homeostatic marker Tmem119 has been shown
to be enriched on microglia, but not BMDMs, in both human
and mouse brain tissue (Bennett et al., 2016). Cx3cr1 (another
homeostatic microglial marker) and Siglec-H are also expressed
by resting microglia, but neither are expressed by activated
microglia or macrophages derived from lung or peritoneum
(Sheng et al., 2015). Conversely, CD49D/ITGA4 was identified
as a marker for BMDMs (Gautier et al., 2012). Importantly,
novel proteomic studies have indicated the influence that the
tumor microenvironment may exert on microglia-specific
biomarkers, altering the phenotype of the analyzed immune
cells and introducing potential confounds to data interpretation
(Bowman et al., 2016). Thus, our understanding of how BMDM
and microglia, respectively, contribute to metastasis progression
in the brain remains in its infancy. Nevertheless, with these
improved tools and greater insight into potential confounds, we
are now in a position to examine these questions more fully.
AMBIGUOUS RESPONSE
The innate role of the cells of the immune system is to
guard, detect and respond to any insult that may disrupt
the regular physiological equilibrium or homeostasis. However,
as a result of their ability to take on an anti-inflammatory
phenotype, microglia/BMDMs are able to advocate a pro-
tumorigenic scenario during cancer and metastasis progression
Sica et al., 2006; Hao et al., 2012; Roesch et al., 2018). This
phenotype exhibits, (i) increased anti-inflammatory cytokine
production, (ii) loss of phagocytic activity, (iii) release of growth
factors, (iv) chemo-attractive effect on peripheral monocytes,
and (v) inhibition of T-cell proliferation within the tumor
microenvironment (Quail and Joyce, 2013).
Immune cells with a pro-inflammatory phenotype have been
described as exerting an anti-tumorigenic (M1 or classical
activation) effect whilst, in contrast, those with an anti-
inflammatory profile (M2 or alternative activation) have shown
tumor-supporting activity (Pukrop et al., 2010; Vicetti Miguel
et al., 2010). The historical view that microglial cells exist in a
balance between two states, pro- (M1) and anti-inflammatory
(M2), is now considered too simplistic. Many groups are
instead focused on defining context-specific microglial activation
and phenotype as a measure of functional diversity. Deep
transcriptomic analysis has yielded a plethora of microglial
genes (e.g., Lgals3, Trem2, NOS2, COX1, etc.) that encompass
the Disease-Associate Microglia (DAM). This characteristic
microglial pattern was first reported by Keren-Shaul et al.
(2017) and aims to characterize the microglial response during
neurodegenerative processes. Further studies (Krasemann et al.,
2017; Deczkowska et al., 2018) have completed the inflammatory
profile of these DAM cells in a broad panel of central diseases
(e.g., Multiple Sclerosis, Alzheimer’s disease, Amyotrophic
Lateral Sclerosis, or Parkinson’s disease) including primary brain
cancer and metastasis to the CNS (Sevenich, 2018). Therefore, it
seems reasonable to accept the existence of a complex microglial
behavior during central disorders, including brain metastasis,
beyond the simplistic M1-M2 definition (Ransohoff, 2016).
However, the molecular pathways underlying the mechanistic
switch during breast cancer brain metastasis progression are still
unknown.
PERSPECTIVES FOR THERAPIES
TARGETING MICROGLIA IN
SECONDARY BRAIN CANCER
The poor bioavailability in the brain of systemically successful
treatments, and the impact of complex and variable
environmental factors has reduced the efficacy of novel
therapies in brain metastasis. In recent years, the inflammatory
microenvironment has shown the potential for exploitation as
both a prognostic and therapeutic tool in various malignancies.
In the following section, we discuss the potential of microglia
modulation as a novel therapeutic strategy in BM.
Immunotherapy
Harnessing the body’s immune response to tumors has
recently shown promise for the treatment of different cancer
types. Current studies are focusing on the use of check-
point blockade treatments not just to stop primary tumor
progression, but also their metastasis to distant organs. The
clinical success of specific immune checkpoint blockade, such
as PD-1 and CTLA-4 (negative regulators of T-cell adaptive
immune function), represent a promising advance in cancer
immunotherapy development (Pardoll, 2012). An important
function of microglial cells (innate immune response) in the
inflammatory microenvironment of BM is T-cell activation via
expression of the HLA ABC/major histocompatibility antigen
class I. Therefore, microglial activation is mandatory for the
induction of a specific immune response including T and B cells
(Graeber and Streit, 2010).
However, as previously described, microglia cells are also
capable of immune suppressive functions. PD-L1 expression,
the ligand of the inhibitory T-cell co-receptor PD1, has been
detected on microglial cells (Magnus et al., 2005). Via activation
of CTLA4 or PD1, microglial cells can suppress the anti-tumor
T-cell response and participate in the generation of an immune
suppressive tumor microenvironment. Microglia have also been
shown to enhance invasion and colonization of brain tissue by
cancer cells by serving both as active transporters and guiding
rails (Berghoff et al., 2015). In an innovative study, Lorger’s
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group described the role of combinative anti-PD-1/anti-CTLA-
4 therapy in a mouse model of melanoma brain metastasis.
They showed the benefit of combining both immune check point
drugs in melanoma brain metastasis treatment aiding CD8+ T
cell intratumoral infiltration. Nevertheless, understanding of the
behavior of the microglial response during immune-check point
blockade therapy is still in its early stages.
Although most immunotherapies have been targeted to the
adaptive immune response, recent studies have begun to focus
on the innate immune response and macrophages in particular.
Studies suggest that microglial cells manifest a pro-inflammatory
phenotype during cancer progression, whilst BMDM play a
more anti-inflammatory role (Cherry et al., 2014; Andreou
et al., 2017; Xing et al., 2018). Most pre-clinical models and
early phase clinical trials focus on modulating the inflammatory
response driven by tumor associated macrophages, rather than
depleting them from the organism (Pyonteck et al., 2013; Quail
and Joyce, 2013). One of the most studied targets for such
phenotypic modulation is the macrophage colony stimulating
factor-1 (CSF1). Several studies using CSF1-R inhibitors have
proved their efficacy by inhibiting altenative-M2 markers on
BMDM in several primary cancers, although its potential role
in BM is still to be elucidated. In the same vein, expression
of the mannose receptor on peripheral monocytes has been
related to anti-inflammatory properties (Chieppa et al., 2003).
Furthermore, we recently demonstrated that selective depletion
of this mannose receptor-expressing subtype of microglia and
BMDMs by intracerebral injection of mannosylated clodronate
liposomes in a mouse model of breast cancer brain metastasis
significantly reduced BM burden over a time-course study
(Andreou et al., 2017).
These promising results in pre-clinical studies could pave
the way for future trials in which the immune response could
be modulated into a more anti-tumorigenic state. However, we
need to be cautious and consider the potential side effects that
these drugs may provoke in healthy organs, as a consequence
of the overstimulation of the immune system. Nevertheless,
the substantial potential gains are likely to outweigh the
possible negative side-effects, as has proven the case with both
chemotherapies and current immunotherapies.
FIGURE 1 | (A) Immunohistochemical image of one brain section from the left striatum of a female SCID mouse injected intracranially with 5×103 MDA231Br-GFP
cells (Day 21). Microglia activation is stained brown (Iba-1, 1:300: Abcam, United Kingdom). This control mouse was treated with PBS via implanted osmotic
minipump throughout the entire time-course study. Inset showing the selected area magnified (20×). Tumor area circumscribed in dotted yellow line. (B) As for (A)
from a mouse treated with L-NAME (30 mg/kg) via osmotic minipump. (C) Graph showing the ratio of microglial activation contained within the left striatum as a ratio
of tumor area. Quantitation of microglia activation in animals treated with L-NAME (n = 6), showed a significant (unpaired Student t-test, p = 0.003. GraphPad Prism,
United States) reduction compared to PBS-treated control (n = 6). Iba-1 expression was measured using an Aperio ImageScope R© (Leica, Germany) algorithm, in
which positive stained (brown) pixels where measured within the left striatum of each animal (n = 6 per group). Scale bar = 300 µm. (D) Schematic of the
experimental model.
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Combinative Approaches
Despite the slight improvement in patient life expectancy, the
survival for BM patients is still measured just in months,
reflecting, in large part, the complex nature of BM disease.
Stereotactic radiotherapy and surgery are keystones for the
management of many different subtypes of metastatic lesions
in the CNS, but still yield relatively little benefit. However,
combination of gold-standard therapies such as ionizing
radiation with novel anti-tumorigenic drugs may lead the
way to achieve better clinical results. For example, anti-
CSF1-R therapies in combination with IR or anti-PD-1 are
currently ongoing in primary brain tumors (Butowski et al.,
2016).
Our group has described several cellular adhesion molecules
specifically upregulated within the tumor-associated microglial
population (Soto et al., 2014, 2016), and inhibition of tumorigenic
molecules such as lymphocyte function-associated antigen 1
(LFA-1) and activated leukocyte cellular adhesion molecule
(ALCAM) have been shown to significantly reduce breast
cancer BM. Additionally, the local inflammatory response
to tumor cells, in which microglia play a pivotal role,
is regulated by a plethora of pro- and anti-inflammatory
cytokines. Moreover, we have shown that activation of enzymes
such as nitric oxide synthase (NOS) and cyclooxygenase-
2 (COX-2) within the TME is key to tumor progression,
and that this is driven by tumor-host cell interactions
through LFA-1 signaling. Recent findings from our group
have shown that selective inhibition of NOS, by L-NAME
administered via osmotic mini-pump, reduced the microglial
response in a breast cancer brain metastasis xenograft model
(Figure 1).
BRAIN METASTASIS TREATMENT
CHALLENGES
Advanced treatments for brain metastasis patients consist of
a combination of surgery, radiation and the administration
of systemic chemotherapeutic drugs. However, these strategies
entail a few limitations depending on location, total tumor mass,
radio-resistant/sensitive histology, etc. Advances in systemically
administered therapies have focused on overcoming these
limitations, but the outcome has varied between no effect on
metastatic burden, undesirable cognitive and physical side effects,
and short transient response on tumor growth arrest with
similarly unsuccessful results long-term (Owonikoko et al., 2014).
Part of the poor improvement afforded by new targeted therapies
reflects restrictions on brain uptake owing to the BBB and the
tumor-brain barrier (TBB) (Gril et al., 2018). Consequently, effort
is now directed at designing novel strategies to either selectively
permeabilise the BBB and TBB at the metastatic foci (Connell
et al., 2013) or to enhance the ability of systemic therapies to cross
the BBB/TBB (Lockman et al., 2010; Gril et al., 2018).
At the same time, a lack of biological understanding of the
long-term impact of newly designed drugs on different cell
populations within the tumor microenvironment, including
microglia, also contributes to the scarce improvement in
BM patient outcome. Moreover, whilst the role of T cells,
microglia and BMDM in brain metastasis progression has
received some attention, the contributions of other immune
cells, such as neutrophils, myeloid-derived suppressor cells
and dendritic cells, have yet to be considered in any
detail.
FUTURE DIRECTIONS
Irrespective of the efficacy of novel targets in brain metastasis,
it seems highly unlikely that single therapies will overcome
this stage of cancer progression. Rather, combinations of
gold-standard therapies such as radiotherapy with molecularly
targeted brain-specific treatments against key components of the
TME may afford increased life expectancy in patients suffering
metastatic spread to the brain.
Understanding the impact of immune check point blockade
not just on T cell biology, but also on microglial behavior
enable further enhancement of the global immune response and
overcome the macrophage/microglia-induced tumor supportive
scenario observed in BM. At the same time, transcriptomic
sequencing of tumor-associated microglia during the course of
brain metastasis may improve our understanding of the pathways
that ultimately lead to the tumor supportive scenario.
Current clinical trials in neurodegenerative disease aim to
reduce the local inflammatory response targeting typical pro-
inflammatory microglia biomarkers (Subramaniam and Federoff,
2017). In a brain metastasis context, the reverse is a key goal
and future directions should include strategies in which the
anti-inflammatory response of microglia is suppressed and their
cytotoxic (pro-inflammatory) response promoted.
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